drugset
drugset / Trial / NCT03401112

A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)

NCT03401112 ↗

Phase 2 Completed 100 enrolled Cardurion Pharmaceuticals, Inc. Imara, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Study of IMR-687 in adult participants with sickle cell anemia (SCA) (homozygous HbSS or sickle-β0 thalassemia).

Timeline

Start
2018-01-26
Primary completion
2020-08-28
Completion
2020-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Tovinontrine Small molecule 100 mg Oral
Subject Tovinontrine Small molecule 200 mg Oral

Indications

sickle cell disease